Product Name:Tofacitinib Citrate
Synonym:Tofacitinib Citrate;Tofacitinibcitrate;540737-29-9;Xeljanz;CP-690550;CP 690550-10;Tasocitinib citrate;Tofacitnib Citrate;Tofacitinib Citratet;Tofacititinib cirate;
Usage:Treat rheumatoid arthritis.
(1).Tofacitinib citrate is a king of drugs developed by the US pharmaceutical company for treating rheumatoid arthritis , for the treatment of methotrexate inadequate response or intolerance to severe active rheumatoid arthritis ( RA) in adult patients. Tofacitinib citrate is approved for the treatment of methotrexate inadequate response or intolerance to severe active rheumatoid joints arthritis (RA) in adult patients.
(2). It can be used as monotherapy or in combination with methotrexate or other non-biological disease-modifying antirheumatic drugs (the DMARD) in combination. This medicine should not be in combination with biological DMARD or strong immunosuppressants (such as cyclosporine and azathioprine) .Tofacitinib citrate is approved by the daily dose of 2 times, each time 5mg. Seven clinical trials evaluated the safety and efficacy of Tofacitinib citrate in moderate to severe active RA in adult patients. In all tests, compared with patients receiving placebo, patients receiving Tofacitinib citrate treatment showed significant improvement in clinical response and physical function.
(3).In Clinical trials, the most common adverse events were upper respiratory tract infection, headache, diarrhea, nasal congestion, sore throat, and nasopharyngitis. Using Tofacitinib citrate was associated with an increased risk of serious infections, including opportunistic infections, tuberculosis, cancer and lymphoma. Tofacitinib citrate product label attaches boxed warning on these security risks.Tofacitinib citrate treatment is also associated with reducing blood cell counts and increasing cholesterol and liver enzyme values.In order to study Tofacitinib citrate long-term impact on heart disease, cancer and severe infections, FDA requires for a post-marketing study, which will evaluate two doses of Tofacitinib citrate therapy, and accept a integration of another group of patients approved by the treatment as a control.